FDA Approves Cancer Breakthrough Pain Drug with Safeguards

The Food and Drug Administration has approved a new opiate drug for severe breakthrough cancer pain.  However, Onsolis® will only be available through a restricted distribution program.

As part of an FDA-required Risk Evaluation and Mitigation Strategy, or REMS, only health care providers, pharmacies, and patients registered with the FOCUS program will be able to prescribe, dispense, and use the medicine.

The FOCUS program will:

Onsolis delivers fentanyl through an absorbable film that sticks to the inside of the mouth.  It can only be prescribed for patients who are already taking another opiate medicine around the clock, considered tolerant to opiates and can safely take high doses of fentanyl.

The drug has a boxed warning that it should not be used for migraines, dental pain, or pain after surgery or by patients who only use it on an as-needed basis. It also warns that it must be kept out of the reach of children and not substituted for other fentanyl products.

Bob Rappaport, MD, director of the Division of Anesthesia, Analgesia and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research (CDER) said,

Onsolis can provide strong pain relief to patients who are opioid tolerant. But for patients who are not opioid tolerant, it can lead to overdose, sudden serious breathing difficulties and death. For this reason, Onsolis should be prescribed only under the safeguards provided by the FDA-required REMS and by health care professionals knowledgeable about Onsolis and the use of potent opioid medications.

Bookmark and Share

This news article was originally posted on July 16th, 2009 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on July 16th, 2009
Tags: cancer pain, fentanyl, Onsolis

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.

First Name

Last Name

Email

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe